99 Tau PET and cognition REFERENCES 1. Schöll M, Maass A, Mattsson N, Ashton N, Blennow K, Zetterberg H, et al. Biomarkers for tau pathology.Mol Cell Neurosci 2019;97: 18-33. https://doi.org/10.1016/j.mcn.2018.12.001 2. Ossenkoppele R, Prins N, Berckel B. Amyloid imaging in clinical trials. Alzheimers Res Ther. 2013;5:36. https://doi.org/10.1186/alzrt195. 3. Yaqub M, Tolboom N, Boellaard R, van Berckel BN, van Tilburg EW, Luurtsema G, et al. Simplified parametric methods for [11C] PIB studies. Neuroimage. 2008;42:76–86. 4. Peretti DE, García DV, Reesink FE, van der Goot T, De Deyn PP, de Jong BM, et al. Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer’s disease PET studies. PLoS One. 2019;14:e0211000. 5. Rodriguez-Vieitez E, Leuzy A, Chiotis K, Saint-Aubert L, Wall A, Nordberg A. Comparability of [18F] THK5317 and [11C] PIB blood flow proxy images with [18F] FDG positron emission tomography in Alzheimer’s disease. J Cereb Blood Flow Metab. 2017;37:740–9. 6. Peretti DE, García DV, Reesink FE, Doorduin J, de Jong BM, De Deyn PP, et al. Diagnostic performance of regional cerebral blood flow images derived from dynamic PIB scans in Alzheimer’s disease. EJNMMI Res. 2019;9:59. 7. Joseph-Mathurin N, Su Y, Blazey TM, Jasielec M, Vlassenko A, Friedrichsen K, et al. Utility of perfusion PET measures to assess neuronal injury in Alzheimer’s disease. Alzheimers Dement. 2018;10:669–77. 8. Chen YJ, Rosario BL, MowreyW, Laymon CM, Lu X, Lopez OL, et al. Relative 11C-PiB delivery as a proxy of relative CBF: quantitative evaluation using single-session 15O-water and 11C-PiB PET. J Nucl Med. 2015;56:1199–205. 9. Ottoy J, Verhaeghe J, Niemantsverdriet E, De Roeck E,Wyffels L, Ceyssens S, et al. 18F-FDG PET, the early phases and the delivery rate of 18F-AV45 PET as proxies of cerebral blood flow in Alzheimer’s disease: validation against 15O-H2O PET. Alzheimers Dement. 2019. https://doi.org/10.1016/j.jalz.2019.05.010. 10. Johnson KA, Schultz A, Betensky RA, Becker JA, Sepulcre J, Rentz D, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol. 2016;79:110–9. 11. Ossenkoppele R, Schonhaut DR, Schöll M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer’s disease. Brain. 2016;139:1551–67. 12. Pontecorvo MJ, Devous MD Sr, Navitsky M, Lu M, Salloway S, Schaerf FW, et al. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Brain. 2017;140:748–63. 13. Leeuwis AE, Benedictus MR, Kuijer JP, Binnewijzend MA, Hooghiemstra AM, Verfaillie SC, et al. Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer’s disease. Alzheimers Dement. 2017;13:531–40. 14. Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62:1091–111. 4
RkJQdWJsaXNoZXIy MjY0ODMw